Savannah Demko

SAN DIEGO — Quantitative magnetic resonance cholangiopancreatography may help assess changes in the biliary tree and aid monitoring of patients with primary sclerosing cholangitis, according to research presented at The Liver Meeting.

Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, discussed the long-term follow-up data of 4-year outcomes from the NATALEE trial.

Trastuzumab deruxtecan, or T-DXd, showed clinical activity in a large population of metastatic HER2-positive breast cancer patients with brain metastases, according to “really impressive” data from DESTINYBreast-12 presented at ESMO Congress.

Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, talked about survival data from KEYNOTE-522 that have been awaited with “a lot of anticipation.”

In a video interview, Nancy Lin, MD, of Dana-Farber Cancer Institute, talked about an analysis of HERA trial data presented at ESMO Congress.

In a video interview, Nancy Lin, MD, of Dana-Farber Cancer Institute, discussed “interesting updates” from the NATALEE trial presented at ESMO Congress.

Nancy Lin, MD, from the department of medical oncology at Dana-Farber Cancer Institute, discussed exciting OS data from the KEYNOTE-522 study presented at ESMO Congress.

Trastuzumab deruxtecan showed substantial and durable overall and intracranial clinical activity in patients with HER2-positive metastatic breast cancer, according to results from the DESTINYBreast-12 trial presented at ESMO Congress.

Breastfeeding appeared safe in women with hormone receptor–positive early breast cancer who temporarily interrupted treatment to attempt pregnancy, according to results from the POSITIVE trial presented at ESMO Congress.

In this video, Lindsey A. George, MD, discussed updated clinical trial data around hemophilia gene therapy presented at ASH Annual Meeting and Exposition.